Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.6700 (-2.95%) ($12.6700 - $12.6700) on Tue. Feb. 7, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.6% (three month average) | RSI | 43 | Latest Price | $12.6700(-2.95%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.5% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(60%) IBB(54%) IWO(45%) IWM(44%) IWC(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.3% in a week (0% probabilities). TBT(-18%) UUP(-11%) VIXM(-10%) VCSH(-6%) VXX(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.3% (StdDev 2.6%) | Hourly BBV | -1.8 () | Intraday Trend | 0% | | | |
|
Resistance Level | $12.9 | 5 Day Moving Average | $13.14(-3.58%) | 10 Day Moving Average | $13.07(-3.06%) | 20 Day Moving Average | $12.9(-1.78%) | To recent high | -6% | To recent low | 23% | Market Cap | $3.272b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |